Biotech Showcase 2015 EBD Group Demy Colton Life Science Advisors Biotech Showcase 2015
Share:
Email this page Share this on LinkedIn Share this on Twitter | print this page

Biotech Showcase™ 2015 Program Overview

The preliminary program for Biotech Showcase™ 2015 will be available soon

Biotech Showcase 2014 program

www.ebdgroup.com/bts/program
Sunday, January 12, 2014
4:00–7:00 pm
Level 4, Cyril Magnin Foyer

All Biotech Showcase attendees are invited to pick up name badges prior to the beginning of the conference on Monday.

Monday, January 13, 2014
7:00 am
Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast
8:00–9:00 am
Workshop
Molecular diagnostics: Poised to improve patient outcomes

Monday, 8:00–9:00 am
Level 4, Mission II

AdvamedDx estimates that diagnostics currently influence as much as 70% of all healthcare decision making. Molecular diagnostics, the next generation of diagnostic tests, provide insights that help physicians determine which therapy or treatment is best for each patient. This paradigm shift toward personalized medicine promises to yield great improvements in the efficacy of treatment, improving patient outcomes and positively impacting the cost of healthcare.

Moderator:
Ed Winnick – Editor-in-Chief, GenomeWeb

Panelists:
  • Paul Billings – CMO, Life Technologies
  • David de Graaf – President and CEO, Selventa
  • Jorge A. Leon – President and CEO, Leomics Associates Inc
  • Steve Lundy – CEO, Venaxis
  • Peter Young – Executive in Residence, AM Pappas & Associates
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00–9:00 am
Biotech Showcase Special Presentation
Biotech Showcase, Streetwise Reports and Sagient Research Present The Life Sciences Report Watchlist 2014

Monday, 8:00–9:00 am
Level 3, Powell

The Life Sciences Report 2013 Watchlist averaged a 35% return in 2013. Can the 2014 Watchlist do the same or better? Attend this special premier presentation at Biotech Showcase and be the first to learn which companies made the 2014 Watchlist based on major catalysts according to analysts at Sagient Research and in-depth company analysis from a panel of industry experts. Get an inside look at stocks and sectors to watch in the coming year.

Welcome:
Karen Roche – President, Streetwise Reports

Moderator:
Mara Goldstein – Managing Director and Senior Biotechnology Analyst, Cantor Fitzgerald

Panelists:
  • Michael G. King, Jr. – Managing Director and Senior Biotechnology Analyst, JMP Securities LLC
  • John McCamant – Editor, Medical Technology Stock Letter
  • George B. Zavoico – Managing Director, Equity Research Analyst, H.C.Wainwright & Co.
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00–9:50 am
Alliance for Regenerative Medicine
State of the Industry Briefing

Monday, 8:00–9:50 am
Level 4, Cyril Magnin Ballroom

The Alliance for Regenerative Medicine's 4th Annual State of the Industry Briefing is a top-level gathering for key stakeholders in the regenerative medicine field, providing a comprehensive overview of the sector's outlook. The program includes a discussion of clinical data inflection points to expect in 2014, as well as a retrospective look at the field's major financing deals including IPOs, reverse mergers and follow-on offerings over the past 12 months. The featured executives will break down for the audience what all of this activity means for the sector's progress, and shed light on the future of both clinical outcomes and fundraising opportunities for the coming year.

Speakers:
  • Robert Brenner – President and CEO, AlloCure
  • Christopher Calhoun – CEO, Cytori Therapeutics
  • Jason Kolbert – Managing Director of Biotechnology, Maxim Group
  • Geoff MacKay – President and CEO, Organogenesis Inc.
  • Keith Murphy – Chairman and CEO, Organovo
  • Andrew Pecora – Chief Visionary Officer, NeoStem
  • Marc Penn – Chief Medical Officer, Juventas Therapeutics; Co-PI of MultiStem Cardiovascular Trial, Athersys
  • Eliseo Salinas – Executive VP, Head of R&D, StemCells, Inc.
  • Michael Schuster – Founding Executive, Head of Global Therapeutic Products, Mesoblast
  • Dave Stadinski – Head of Equity Capital Markets, Piper Jaffray
  • Jeffrey Walsh – Chief Operating Officer, bluebird bio
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm Company Presentations ►

Private Biotech
Public Biotech

12:00–1:40 pm
Lunch Plenary
New models in biotechnology: Innovative structures, financing options and risk sharing opportunities

Monday, 12:00–1:40 pm
Level 4, Cyril Magnin Ballroom

With the collapse of the IPO market several years back, alternative corporate structures, financing options and risk sharing strategies were initiated as a means of filling the financing void. Now that the IPO markets have returned and some fortunate VC firms have replenished their coffers to fund small and mid-stage companies, what role will these alternatives play going forward?

Moderator:
Rich Rieger – VP, Campbell Alliance

Panelists:
  • Martin J. Birkhofer – Chief Medical Officer, inVentiv Health Clinical
  • Bruce Booth – Partner, Atlas Venture
  • Paul J. Hastings – President and CEO, OncoMed Pharmaceuticals
  • Gregory C. Simon – CEO, Poliwogg Holdings, Inc.
  • Alex Zisson – Partner, Thomas, McNerney & Partners LLC
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:45–5:30 pm Company Presentations ►

Private Biotech
Public Biotech

1:30–6:00 pm
One-to-one Meetings ►
Tuesday, January 14, 2014
7:00 am
Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast
8:00–9:00 am
Workshop
Japanese Emerging Companies

Tuesday, 8:00–9:00 am
Level 4, Hearst

8:00–8:10  BioComo, Inc.
8:10–8:20  BioMedCore, Inc.
8:20–8:30  M Bio Technology, Inc.
8:30–8:40  NB Health Laboratory Co., Ltd.
8:40–8:50  Nomadic Bioscience Co., Ltd.
8:50–9:00  Tokyo Future Style, Inc.

Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm
One-to-one Meetings ►
8:00–9:00 am
Workshops
Parkinson's disease: On the threshold of new therapies in an area of high unmet need

Tuesday, 8:00–9:00 am
Level 4, Mission II

Current therapies for Parkinson's disease treat the symptoms of this neurodegenerative disease but do not prevent, slow or halt its progression. In addition, symptomatic treatments fail to address all the effects of Parkinson's and create problems of their own, such as dyskinesia and "off" episodes. This opportunity to greatly impact patients' lives has been of increasing interest to both researchers and investors alike. Investigators are on the cusp of discovery and drug development that will improve current symptomatic treatments, allow for earlier diagnosis, and provide the cure for Parkinson's that millions desperately seek. Greater insight into the genetics of Parkinson's, robust characterization of drug targets and, perhaps most importantly, coordination of efforts between nontraditional partners have brought us closer than ever to a disease-modifying therapy. Join this workshop to hear from a panel of biotech leaders on their projects and partnerships that will change the Parkinson's prognosis.

Moderator:
Saira Ramasastry – Managing Partner, Life Sciences Advisory, LLC

Panelists:
  • Oded S. Lieberman – CEO, NeuroDerm, Ltd.
  • Erich Mohr – Chairman and CEO, MedGenesis Therapeutix Inc.
  • Jonathan Solomon – CEO, NeuroPhage
  • Ebrahim (Eboo) Versi – Board Chairman, Chief Medical Officer, Eboo Pharmaceuticals, Inc
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Big Data in drug discovery

Tuesday, 8:00–9:00 am
Level 3, Powell

From Google tracking flu outbreaks via search behavior to companies seeking to reposition drugs based on in silico analysis, examples abound of healthcare being affected by Big Data. But unlike most markets already tackled by Big Data, life sciences markets are heavily regulated and traditional methods are deeply entrenched. Still, Big Data is making inroads and our panelists are making it happen. Join us as we discuss the impact of data analytics and computational tools on drug discovery, VC investment and healthcare.

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • Gini Deshpande – CEO, NuMedii
  • Mark Murcko – Principal, Disruptive Biomedical
  • Feyi Olopade – Founder and CEO, CancerIQ Inc.
  • Ajit Singh – Managing Director, General Partner, Artiman Ventures
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
FDA: Where it's going and how it affects biotech

Tuesday, 8:00–9:00 am
Level 4, Mission I

Breakthrough designations, fast track, priority review, accelerated approval: Given the current spotlight on programs intended to speed up development and regulatory review, how is this changing biotech and what should an investor look at? What are the benefits of these programs and do they increase a product's value? How do your portfolio companies apply?

Moderator:
Brenda Huneycutt – Senior Manager, Avalere Health

Panelists:
  • Jenny Gaffney – Director, Avalere Health
  • Jonathan S. Leff – Partner, Deerfield Management and Chairman, Deerfield Institute
  • Linda Peters – VP, Global Regulatory Affairs, Baxter Healthcare
  • Michelle Rohrer – VP US Regulatory Affairs, Genentech Roche
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm Company Presentations ►

Private Biotech
Public Biotech

12:00–1:40 pm
Lunch Plenary
The changing dynamic of the drug development ecosystem

Tuesday, 12:00–1:40 pm
Level 4, Cyril Magnin Ballroom

Traditionally, drug development programs haven't focused on the needs of patients or payers. It was a "build it and they will come" mentality. Now, as the healthcare ecosystem evolves, patients, payers and investors are seeking more of a voice in drug development decisions. This panel will discuss how biopharmaceutical companies are working to balance these new forces and what impact these players will have on how drug development is approached in the future.

Moderator:
Ellen B. Corenswet – Partner, Covington & Burling LLP

Panelists:
  • Karen Bernstein – Co-Founder, Chairman and Editor-in-Chief, BioCentury
  • Anton Gopka – Managing Partner, RMI Partners
  • Dan Mendelson – CEO, Avalere Health
  • Dennis Purcell – Senior Managing Director, Aisling Capital
  • Evonne Sepsis – Managing Director, ESC Advisors
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:45–5:30 pm Company Presentations ►

Private Biotech
Public Biotech

1:30–6:00 pm
One-to-one Meetings ►
Wednesday, January 15, 2014
7:00 am
Level 4, Cyril Magnin Foyer
Registration Opens and Continental Breakfast
8:00–9:00 am
Workshops
Cancer checkpoints: Harnessing the immune system to fight cancer

Wednesday, 8:00–9:00 am
Level 3, Powell

The understanding of and ability to modulate the checkpoint pathways associated with cancer are at the forefront of an exciting new class of therapeutics designed to turn on the immune system to recognize and fight cancer.

Moderator:
Mark J. Simon – Advisor, Torreya Partners

Panelists:
  • Bahija Jallal – Executive VP, AstraZeneca; Head, MedImmune
  • Nils Lonberg – Senior VP, Biologics Discovery, Bristol-Myers Squibb
  • Ronald A. Pepin – Senior VP and Chief Business Officer, Celldex Therapeutics
  • Michael Schickler – CEO, CureTech Ltd
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Sources of alternative funding in difficult times

Wednesday, 8:00–9:00 am
Level 4, Mission II

In today's market, funding for early stage companies is increasingly challenging, particularly for pre-revenue companies. Panelists will discuss the current investment environment for start-up medical technology companies and the latest strategies they should consider when seeking funding, including alternative funding sources for pre-revenue and emerging companies. Additionally, the panel also examines some of the unique issues related to alternative sources of funding, including hand-off to more traditional funding sources as companies reach mature revenue streams.

Moderator:
Christian L. Haller – President, RavenOye Group

Panelists:
  • Doug Armstrong – Chief Business Officer, Dawson James Securities
  • Michelle Basil – Chair, Life Sciences Practice Group, Nutter McClennen & Fish
  • Larry Gerrans – President and CEO, Sanovas
  • William S. Podd – President and CEO, Landmark Capital
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm
One-to-one Meetings ►
8:00–9:00 am
Workshop sponsored by BaselArea
Life sciences investment and financing climate in Europe

Life sciences investment and financing climate in Europe
Wednesday, 8:00–9:00 am
Level 4, Mission l

Venture capital financing is far behind in Europe versus the US. However, Europe still has a strong biotech Industry. We discuss where financing in Europe is coming from with some of the key investors in Europe. What role do pharma, family offices and government play in the future of the European biotech industry? How much does location matter for financing, where do companies get their funding from, and what are the alternatives besides VC?

Moderator:
Patrik Frei – CEO, Venture Valuation

Panelists:
  • Jasper Bos – Director, Merck Serono Ventures at Merck Serono
  • Gabriela Guentherodt – Director, North America, BaselArea Economic Promotion
  • Simon Nebel – Managing Partner, Aravis SA
  • Thom Rasche – Partner, Earlybird Venture Capital
  • Carlo Rizzuto – Operating Principal, Versant Ventures
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–12:00 pm Company Presentations ►

Private Biotech
Public Biotech

12:00–1:40 pm
Lunch Plenary
How do you define value?

Wednesday, 12:00–1:40 pm
Level 4, Cyril Magnin Ballroom

The market for healthcare is evolving as a variety of forces converge to change the way the industry defines value. New technologies such as personalized medicine are changing the way drugs are marketed; patient groups are seeking greater access to innovative therapies; payers are demanding cost-effective treatments. Meanwhile, shareholder and investors require a reasonable ROI. The environment is made more complex as policy makers around the world try to respond to these market forces with reforms and revisions to regulatory regimes. How do biopharmaceutical companies balance these often competing interests to define value in the 21st Century? Our panel will discuss how industry should best engage with these stakeholders to develop a workable definition of value that still fosters innovation.

Moderator:
Ben Bonifant – Partner, Triangle Insights Group

Panelists:
  • Ron Cohen – President and CEO, Acorda Therapeutics, Inc.
  • Marc Dunoyer – CFO, AstraZeneca
  • Craig D. Gordon – VP, Investment Analyst, Capital Research
  • Evan McCulloch – VP, Portfolio Manager and Research Analyst, Franklin Equity Group
  • James Sabry – Senior VP, Genentech Partnering, Genentech
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
1:45–5:00 pm Company Presentations ►

Private Biotech
Public Biotech

1:30–5:00 pm
One-to-one Meetings ►
5:00–6:00 pm
Level 4, Cyril Magnin Foyer
Closing Reception and Panel
The last word

Wednesday, 5:00–6:00 pm
Level 4, Cyril Magnin Foyer

Join our panel of experts as they look back over the themes that emerged during the conference and look forward at the trends and deals that will shape 2014. We expect a provocative and candid discussion—which combined with a few celebratory drinks may inspire some downright irreverent insights you won't hear anywhere else. Don't miss the last word on the week that sets the tone for healthcare investing and partnering for the coming year.

Moderator:
Kimberly Ha – Global Editor, BioPharm Insight

Panelists:
  • Stephen G. Brozak – President, WBB Securities LLC
  • Fabrice Egros – Managing Partner, RMI Partners
  • Deshan (Desh) S.K. Govender – Portfolio Manager, Healthcare, Cedar Lane
  • Anthony Y. Sun – Partner, Aisling Capital
Biotech Showcase™ 2014
Share this:Email this pageShare this on LinkedInShare this on Twitter
Sponsored by:
RMI PartnersRMI Partners Streetwise ReportsStreetwise Reports
Arrow Up


© 2009–2014 EBD Group, Inc.
Biotech Showcase EBD Group Demy-Colton